A large claims study tracked menopause hormone therapy initiation and first treatment episodes, raising questions about goals and clinical follow-up.
On October 28, 2026, Patient Care Online reported late-breaking findings on systemic menopause hormone therapy presented at The Menopause Society’s 2026 Annual Meeting in San Diego. The retrospective insurance-claims analysis examined how often women started treatment after a natural-menopause diagnosis and how long their first recorded treatment episode continued.
The starting point in public guidance is an individual discussion about treatment benefits and risks. The U.S. Office on Women’s Health says benefits are more likely to outweigh risks for women who start hormone therapy before age 60 or within 10 years of menopause. It advises discussing personal benefits and risks with a healthcare provider.
The new analysis adds a different question to that framework: what happens after a menopause diagnosis and after treatment begins? Its contribution concerns recorded treatment patterns rather than a replacement for individualized care.
That distinction keeps the research in perspective. A prescription is one part of a treatment decision, while expectations and opportunities to revisit the plan also deserve attention. For background, a broader explanation of hormone therapy decisions can help place these findings within the wider conversation.
According to Patient Care Online’s study report, researchers used MarketScan insurance-claims data from 2009 through 2022 to examine initiation and persistence after natural menopause.
Taken together, the findings direct attention to both entry into treatment and what follows. The initiation percentage answers one question about recorded care. The first-episode results answer another question about continuation after treatment has begun.
The study arrives within a changing treatment-information landscape. According to the U.S. Office on Women’s Health, the U.S. Food and Drug Administration requested revisions to some hormone-therapy label warnings in 2025. In February 2026, it approved updated labeling for six products.
The approved changes removed cardiovascular disease, breast cancer and probable dementia statements from the boxed warning. Risk information remains elsewhere in labeling. The boxed endometrial-cancer warning remains for whole-body estrogen-only products.
These were changes to how information appeared in labeling, not a removal of every risk from treatment information. The Office on Women’s Health continues to advise a discussion of individual benefits and risks with a provider.
The timing also matters when reading the claims study. Its records came from 2009 through 2022, before these labeling revisions. The revisions belong in the context of present-day discussions rather than serving as an explanation for the treatment patterns recorded in the analysis.
The findings are preliminary meeting results. The available report does not provide a full methods paper or detailed limitations, and an insured U.S. claims population is not a complete account of every woman’s menopause care.
The records do not establish why individuals declined treatment or ended an initial episode. They do not explain women’s symptoms, preferences or full medical histories. Nor do they establish whether someone changed treatment or sought other care. Ending an initial episode should therefore not be read as proof that a woman permanently stopped all hormone therapy.
The low initiation percentage alone does not establish undertreatment. The analysis also did not compare hormone therapy with nonhormonal treatment or no treatment, so it cannot rank those choices for an individual woman.
In the related interview, Sriprasert identified access to care, clinician-patient interactions and underlying medical conditions as potential influences on starting or continuing therapy. Those are possible explanations rather than causes demonstrated by the claims analysis. The demographic associations likewise do not establish what caused a particular woman’s treatment pattern.
The practical response is to make the purpose of treatment explicit. A conversation with a qualified clinician can begin with the concern being addressed and the outcome that would make treatment worthwhile to the woman herself.
Useful questions include:
These questions translate a population-level finding into a more useful individual conversation. They keep the focus on a woman’s reasons for seeking care rather than on whether she falls within the group that starts therapy.
The study’s initiation percentage is a description of what happened in its records. It is not a target that an individual needs to meet. A well-informed discussion should leave room for a decision that reflects personal priorities alongside clinical judgment.
The first-treatment-episode findings make follow-up a central practical issue. Starting therapy need not be treated as the end of the discussion about expectations or concerns.
Questions about follow-up can be raised during the initial conversation rather than saved until something feels unclear:
These are discussion prompts, not a fixed monitoring schedule. Decisions about the timing and content of follow-up belong with the woman and her clinician.
The useful shift is from asking only whether treatment was started to asking how the decision will be reviewed. That makes space for a woman’s experience after the prescription, including whether the original goals remain relevant and whether she feels adequately informed about the next step.
Alternatives belong in the same conversation about goals. A woman deciding whether to start hormone therapy may want to understand other approaches, while someone revisiting an existing plan may have a different set of questions.
Refemina’s overview of hormonal, nonhormonal and lifestyle approaches offers background for organizing those questions. Choosing among them remains an individual clinical discussion.
The useful editorial focus is the quality of the decision rather than a preferred treatment outcome. Understanding the intended benefit, the available choices and the route back to care gives the research practical relevance without turning a treatment statistic into a judgment about women’s choices.
Going forward, the study’s clearest contribution should be to bring treatment goals and follow-up into the same clinical conversation, with attention to what happens after an initial prescription.
Low hormone-therapy initiation can become another reason to portray menopause as a problem with a single medical answer. Refemina’s research-led coverage separates treatment evidence from hormone and supplement hype, helping women understand changing bodies without reducing strength or confidence to whether they use a particular therapy.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources